Janssen, VLF Expansion

BSL-2 vaccines production facility expansion for JBV, Leiden to accommodate the production of the COVID-19 vaccines from 2021 on.

Location: Netherlands
Sector: Biopharmaceutical

About This Project

BSL-2 vaccines production facility expansion for JBV, Leiden to accommodate the production of the COVID-19 vaccines from 2021 on.

DPS developed the Architectural and Engineering design of a BSL-2 vaccines production facility expansion for JBV, Leiden to accommodate the production of the COVID-19 vaccines from 2021 on, using a novel vaccine platform process.

JBV's aim was to erect a new building connected with live current VLF facility within a very aggressive schedule, concept design to IOQ in 8 months.

Process / Support Systems

Our scope included Conceptual Study, Basic and Detail Design, Construction Management and Commissioning & Qualification support in a Client representative role during the project execution.
The projects main purpose was to equip JBV to produce a portion of the two billion COVID-19 vaccines on behalf of Johnson & Johnson (J&J).

DPS team’s vaccine and project delivery expertise enabled us to design the new facility according to the current practices in JBV VLF vaccines production facility, with enough flexibility to accommodate the production of 1,2 billion COVID-19 vaccine doses per year and provide sufficient floor space for additional capacity and GMP enhancements. This included physical expansion of the building (approx. 3,000m²), clean room installations, utility capacity upgrade and process equipment upgrade.

Facility Features

The new facility was designed and constructed within an existing parking lot area over two levels and connected with a live production facility. The civil scope included replication of the existing production units and presented a seamless impression on the overall building.

Achievements

The design, construction and start-up of this facility required a tight schedule and significant intrusion into / alongside live operating, highly contained, vaccine manufacturing facilities. No unscheduled shutdowns occurred and all timelines and budget targets achieved.

Back to top